Syphilis Immunoassay Diagnostics Market Report 2024

The syphilis immunoassay diagnostics market size has grown strongly in recent years. It will grow from $29.08 billion in 2023 to $31.25 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth observed in the historical period can be attributed to socioeconomic factors such as the prevalence of sexually transmitted diseases (STDs), an increase in unidentified sexual encounters, rising incidences of severe syphilis infections, government initiatives aimed at healthcare improvement, and an increased focus on early disease detection.

The syphilis immunoassay diagnostics market size is expected to see strong growth in the next few years. It will grow to $42.17 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The anticipated growth in the forecast period can be attributed to several factors, including the rapid expansion of the high-risk population, heightened awareness about partner notification programs, increasing prevalence rates, growing recognition of syphilis immunoassay diagnostics, and an upsurge in government healthcare expenditures. Key trends expected in this period encompass the adoption of innovative technologies, the development of rapid point-of-care tests, rising demand for home test kits, advancements in laboratory testing methods, and the expansion of diagnostic laboratory techniques.

The anticipated growth of the syphilis immunoassay diagnostics market is expected to be driven by the increasing incidence of sexually transmitted diseases (STDs), also known as sexually transmitted infections (STIs), which are primarily transmitted through sexual contact including vaginal, anal, and oral intercourse. Factors contributing to the rise in STDs include decreased condom use, antibiotic resistance, insufficient sexual education, changes in social behaviors, stigma, reduced funding for STD programs, and increased mobility and travel. Syphilis immunoassay diagnostics play a crucial role in the detection and management of STDs by offering accurate and timely identification of syphilis infections. This enables healthcare providers to initiate appropriate treatment and preventive measures effectively. For example, in January 2024, the Centers for Disease Control and Prevention (CDC), a US-based government agency, reported approximately 2.54 million cases of sexually transmitted diseases in 2021, up from 2.4 million in 2020. This increase underscores how the rising prevalence of sexually transmitted diseases is driving demand within the syphilis immunoassay diagnostics market.

Major companies in the syphilis immunoassay diagnostics market are prioritizing the development of innovative solutions, including rapid syphilis tests, to enhance the efficiency and accuracy of syphilis detection. Rapid syphilis tests are user-friendly, point-of-care tools that detect syphilis antibodies in blood or bodily fluids within minutes, facilitating prompt diagnosis and early treatment. For example, in February 2023, Chembio Diagnostics Inc., a US-based company specializing in point-of-care diagnostics for infectious diseases, received a CLIA waiver from the FDA for its DPP HIV-Syphilis System. This dual rapid test is designed to simultaneously detect antibodies to HIV 1/2 and Treponema pallidum, the bacterium that causes syphilis. Conducted in just 15 minutes, this test aims to enhance diagnostic accuracy and treatment efficacy, particularly in preventing mother-to-child transmission of syphilis and reducing the risk of HIV transmission among individuals with syphilis.

In April 2023, Biosynex SA, a France-based company specializing in syphilis immunoassay diagnostics, acquired Chembio Diagnostics, Inc. for $17.2 million. This strategic acquisition aims to bolster Biosynex's market footprint in North America by leveraging Chembio's established portfolio of FDA-approved products and expertise in rapid diagnostic tests. Chembio Diagnostics Inc., based in the United States, is renowned for its focus on point-of-care diagnostics for infectious diseases, including syphilis.

Major companies operating in the syphilis immunoassay diagnostics market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers, Becton Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories Inc., Meril Life Sciences Pvt. Ltd., Randox Laboratories Ltd., SEKISUI Diagnostics, Bloodworks Northwest, LetsGetChecked, Everlywell Inc., ACON Laboratories Inc., Trinity Biotech, Fujirebio, CTK Biotech Inc., bioLytical Laboratories Inc., AdvaCare Pharma, MyBioSource.com, Gold Standard Diagnostics Frankfurt GmbH, Newmarket Biomedical Ltd, InTec PRODUCTS INC., NuGenerex Diagnostics LLC.

North America was the largest region in the syphilis immunoassay diagnostics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the syphilis immunoassay diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the syphilis immunoassay diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Syphilis immunoassay diagnostics refer to laboratory tests designed to detect antibodies or antigens associated with the bacterium treponema pallidum, the causative agent of syphilis. These diagnostics utilize immunoassay techniques to detect specific immune responses present in the blood. The primary objective of syphilis immunoassay diagnostics is to accurately diagnose syphilis infections, facilitating prompt and effective treatment.

Key products in syphilis immunoassay diagnostics include analyzers, reagents, kits, and related items. Analyzers are devices employed in laboratories to analyze samples for the presence of syphilis. Various technologies utilized include chemiluminescence immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), among others. These diagnostics cater to applications in both men and women and serve diverse end-users such as hospitals, blood banks, diagnostic laboratories, and others.

The syphilis immunoassay diagnostics market research report is one of a series of new reports that provides syphilis immunoassay diagnostics market statistics, including the syphilis immunoassay diagnostics industry global market size, regional shares, competitors with syphilis immunoassay diagnostics market share, detailed syphilis immunoassay diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the syphilis immunoassay diagnostics industry. These syphilis immunoassay diagnostics market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The syphilis immunoassay diagnostics market consists of revenues earned by entities by providing services such as sample collection services, laboratory testing services, point-of-care testing services, and consultation and follow-up services. The market value includes the value of related goods sold by the service provider or included within the service offering. The syphilis immunoassay diagnostics market also consists of sales of rapid plasma reagin (RPR) tests, fluorescent treponemal antibody absorption (FTA-ABS) tests, point-of-care (POC) tests, western blot assays, and multiplex immunoassays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.